Home > Newsletters > Drug Industry Daily > Gilead’s PAH Candidate Scrapped After Missing Primary Endpoint in Study
Drug Industry Daily
Aug. 23, 2012 | Vol. 11 No. 166
Gilead’s PAH Candidate Scrapped After Missing Primary Endpoint in Study
Gilead Sciences’ pulmonary arterial hypertension (PAH) drug cicletanine did not meet its primary endpoint in a Phase II trial, leading Gilead to terminate the study and drop plans to further develop the drug for PAH.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.